Welcome! As the Novartis team in Brussels, we represent our company on European level and operate as the connecting piece between corporate, EU and trade associations. 

Learn more about our priorities, how we reimagine medicine, get to know our team and stay in touch with us on Twitter: @NovartisEU!

Our priorities

To reimagine medicine is our overarching goal, therefore we’re focusing on the pharma review, corporate sustainability due diligence and various therapeutic areas.

General Pharmaceutical Legislation

The General Pharmaceutical Legislation is a once-in-a-generation opportunity to refine and evolve Europe’s regulatory framework – for a better future for patients and industry.

People brainstorming

Corporate Sustainability Due Diligence

Due diligence on human rights and environmental sustainability is strongly embedded into Novartis’ business.

Scientist in the lab Saluggia Italy

Therapeutic areas

At Novartis, we invest in the most promising frontiers of science, the most exciting innovations in the business of medicine, and the most significant healthcare needs.

Novartis has a strong footprint in Europe


Euros of R&D investments in Europe

45 000

Employees in Europe, 10 000 in R&D


Sites in Europe, from R&D to manufacturing to commercial


Academic and industry alliances in Europe

Trade associations



Stands for European Federation of Pharmaceutical Industries and Associations representing biopharmaceutical industry operating in Europe. EFPIA has a direct membership of 36 national associations and 39 leading pharmaceutical companies.

Learn More



Is Europe's trade body for innovative companies working in the field of pharmaceuticals and medical technologies who are active in research, development of pharmaceuticals, biotechnologies and medical devices.

Learn More



The European Association for Bioindustries, promotes an innovative and dynamic European biotechnology industry. They represent 78 corporate, associate members and bioregions & 15 national biotechnology associations representing over 1800 biotech SMEs.

Learn More